Navigation Links
Access Pharmaceuticals Presents New Data on the Company's Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
Date:5/28/2008

ored by a major pharmaceuticals company.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; and Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial a
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
2. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
3. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
4. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
5. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
6. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
7. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
10. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
11. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Larry J. Merlo , President and CEO of ... the National Press Club in Washington, D.C. ... stop selling tobacco products and its leadership in driving the ... "Dramatic changes in our health care system pose enormous challenges ... said. "CVS Health has a truly unique combination of business ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
(Date:9/19/2014)... at Jacksonville,s campus of Mayo Clinic have discovered a ... to both overproduction of toxic protein in the brains ... loss of communication between neurons both significant contributors ... the online issue of Neuron , ... drugs "may rejuvenate or rescue this pathway," says the ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- When it ... deaths in the United States, while the District of ... Over the past decade, deaths from gun-related violence -- ... across the United States, the study revealed. Hawaii,s rate ... end of the spectrum, the District of Columbia had ...
(Date:9/19/2014)... Shahram Majidi, M.D., a second-year resident in ... University School of Medicine and Health Sciences, received ... to study the presence of diffuse brain swelling ... , "According to epidemiological studies, intracerebral hemorrhage accounts ... but is the least treatable form of stroke, ...
(Date:9/19/2014)... September 19, 2014 Top 10 ... recently announced that HostGator.com, GoDaddy and Bluehost are ... These companies are the most recommended suppliers for ... Europe to buy high quality Linux hosting (including ... ) is one of many top hosting companies ...
(Date:9/19/2014)... Capital Region Periodontics and Dental Implants, ... announce the latest addition to their treatment options ... needing dental implants. Often referred to as the ... fear factor normally associated with traditional gum surgery. ... make, this procedure a very attractive oral surgery ...
Breaking Medicine News(10 mins):Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3
... in animal study , WEDNESDAY, Nov. 25 (HealthDay News) ... effectively as some synthetic drugs, English researchers report. , ... Hyptis crenata to treat a range of ... This study is the first to scientifically prove the ...
... , SAN FRANCISCO, Nov. 25 ... color cosmetics and advanced skin care dedicated to providing prestige ... prestige skin care and color cosmetic brand to launch under ... in San Francisco and Toronto, was founded and is managed ...
... ... , is launching a new website utilizing the latest internet technology to educate visitors ... media platforms to create an interactive web experience that’s designed to be an informative ... ...
... , WASHINGTON, Nov. 23 The American ... education, and media company, are launching "Explore the Mystery of ... the fields of science and medicine, in addition to exposing ... hematologists may remember watching a cartoon in grade school about ...
... ... Partner for Anthem Blue Cross, is working to raise awareness during the November 15 ... a zero-cost PPO Medicare Advantage plan. Freedom Blue PPO plans from Anthem Blue Cross ... ...
... radiation oncologists use advanced imaging techniques such as positron emission ... (4DCT) for target delineation (to locate the tumor and other ... in the December issue of the Journal of the ... ). In defining the target, the radiation oncologist draws ...
Cached Medicine News:Health News:Pari Beauty Professional Artistry 2Health News:Richmond, Virginia Plastic Surgeon Launches State-of-the-Art Breast Surgery Website 2Health News:Richmond, Virginia Plastic Surgeon Launches State-of-the-Art Breast Surgery Website 3Health News:Richmond, Virginia Plastic Surgeon Launches State-of-the-Art Breast Surgery Website 4Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 2Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 3Health News:BenefitPackages.com Reveals the Truth About No or Low Cost Medicare Supplement Plan Options Including Anthem Blue Cross Freedom Blue Regional PPO 2
...
Listeria Enrichment Broth...
1.7% Tryptone, 0.3% Soytone, 0.5% Sodium Chloride, 0.25% Dextrose, 0.25% Potassium Phosphate....
... accurately and conveniently controls the temperature at your ... temperature levels up to 99 C*, with the ... low as 5 C. The thermoblocks for 0.2 ... and microplates enable a high degree of flexibility ...
Medicine Products: